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Abstract: Behçet’s disease is an autoinflammatory vasculitis of unknown origin characterized 
by recurrent oral and genital ulcers, uveitis, arthritis and skin lesions. Additionally, involvement 
of the gastrointestinal tract, central nervous system and large vessels may occur. The disease 
is prevalent in countries along the ancient Silk Road from Eastern Asia to the Mediterranean 
Basin. Many treatment modalities are currently available. The choice of treatment depends 
on organ involvement and severity of disease. Topical treatment with corticosteroids is often 
sufficient for mucocutaneous involvement, however for more severe disease with vasculitis or 
neurological involvement a more aggressive approach is warranted. Newer drugs (biologicals) 
influencing cytokines and thereby T-cell function are promising with an acceptable side effect 
profile. Unfortunately, reimbursement of the costs of biologicals for rare disease is still a 
problem in various countries. In this report we discuss the current treatment modalities for 
Behçet’s disease.
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Introduction
Behçet’s disease is an inflammatory disorder characterized by recurrent oral and genital 
ulcers, uveitis, and skin lesions.1,2 The first series of patients with Behçet’s disease was 
already published in 1937 as a triad of these symptoms.3 Additionally, involvement 
of the gastrointestinal tract, central nervous system, and large vessels may occur, 
although less frequently. As in other immune-mediated disorders, Behçet’s disease is 
characterized by attacks rather than by a persistent inflammatory disease.4
Cases of Behçet’s disease cluster along the ancient Silk Road, which extends from 
eastern Asia to the Mediterranean basin. The reported prevalence in Turkey varies 
between 110 and 420 per 100,000.5 In Western countries however the prevalence is 
probably less than 1 per 100,000 in Caucasians. It is believed that both genetic and 
environmental factors contribute to the development of the disease.6,7 Men are affected 
slightly more often than women.
Susceptibility to Behçet’s disease is strongly associated with the presence of the 
human leukocyte antigen (HLA)-B51 allele and its presence is also strongly associated 
with a more aggressive course.8 The cause of Behçet’s disease is however still unknown. 
Infections, both viral and bacterial, may play a role.
Although the exact cause of Behçet’s disease remains to be elucidated, it is clear 
that neutrophils interacting with T-cells play an important role in the pathophysiology. 
Activated T-cells produce tumor necrosis factor-α (TNF-α), which in turn leads to 
production of other proinflammatory cytokines like interleukin-1 (IL-1) and IL-6 Therapeutics and Clinical Risk Management 2009:5 386
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by other immune cells. These proinflammatory cytokines 
stimulate migration and activation of leucocytes, thereby 
causing a local inflammatory response.2 A disturbed func-
tion of regulatory T-cell may also play a role. Eventually 
vessel damage occurs, as can be seen in biopsies taken from 
Behçet’s lesions from various sites involved.4
Clinical picture
Diagnosis
Currently the diagnosis of Behçet’s disease is often based on 
the criteria as proposed by the International Study Group for 
Behçet’s disease in 1990.9 To fulfil these criteria, recurrent 
oral ulcers must be present together with two or more of 
the following; recurrent genital ulceration, eye lesions, 
skin lesions, or a positive pathergy test (Table 1). This test 
consists of pricking a sterile 20G needle into the patient’s 
forearm. The results are judged to be positive when the 
puncture causes an aseptic erythematous nodule or pustule 
that is more than 2 mm in diameter at 24 to 48 hours. At the 
reaction site there is initially an accumulation of neutrophils 
followed by the accumulation of mononuclear cells.10 The 
pathergy test is sometimes considered pathognomonic for 
the disease but can also be positive in other diseases like 
pyoderma gangrenosum.11
Clinical manifestations
As mentioned above, all patients have recurrent oral aphthous 
ulceration at some time in the clinical course. Recurrent oral 
ulceration is often the presenting sign. Lesions are painful, 
last about 10 days, and heal without scarring. Genital ulcers 
are also painful, but often heal with scarring.
Ocular involvement is common and occurs in approxi-
mately 70% of patients and is associated with a high risk of 
blindness. Ocular features of Behçet’s disease are anterior 
uveitis, retinal vasculitis (both veins and arteries), optic 
neuropathy, retinal infiltrates, and vitritis.2
Various types of skin involvement can be seen. Erythema 
nodosum occurs frequently and is more common in women. 
Pseudofolliculitis and acneiform nodules are more common 
in male patients and are distributed on the back, face, and 
neck, especially along the hairline.2
The features of Behçet’s disease, however, are not limited 
to the diagnostic criteria. The syndrome can present in a 
myriad of ways and may involve nearly every organ system. 
In fact, morbidity and mortality predominantly result from 
vasculitis in large vessels, cerebrovascular disease, and 
gastrointestinal involvement. The latter is often difficult to 
distinguish from Crohn’s disease.2
Current treatment options
First of all we must state that unfortunately the level of evidence 
is limited in most of the treatment regimens in Behçet’s disease 
since there are few randomized controlled trials.
Treatment of patients with Behçet’s disease is guided by 
organ involvement (Table 2). Topical steroids are usually 
effective for mucocutaneous involvement. Some patients 
respond insufficiently and additional treatment may be neces-
sary in these cases. Colchicine is often believed to be effective 
for refractory oral ulcers. A double-blind study conducted 
in 1980 did not show a statistically significant reduction in 
the recurrence of both oral and genital ulcers compared to 
placebo.12,13 In a double-blind trial with 116 patients in 2001, 
Yurdakul and colleagues found that colchicine reduced the 
occurrence of genital ulcers and erythema nodosum and 
arthritis in both men and women.14 Perhaps colchicine is more 
effective in women than in men. Thalidomide has also been 
shown to be effective in patients with mucocutaneous lesions 
refractory to treatment with colchicine. Thalidomide exerts 
Table 1 international study group criteria for Behçet’s disease
Finding Definition
Recurrent oral ulceration Minor aphthous, major aphthous, or herpetiform ulcers observed 
by the physician or patient, which have recurred at least three times 
over a 12-month period
Recurrent genital ulceration Aphthous ulceration or scarring observed by the physician or patient
eye lesions Anterior uveitis, posterior uveitis, or cells in the vitreous on slit-lamp 
examination; or retinal vasculitis detected by an ophthalmologist
Skin lesions erythema nodosum observed by the physician or patient, 
pseudofolliculitis, or papulopustular lesions; or acneiform nodules 
observed by the physician in a post-adolescent patient who is not 
receiving corticosteroids
Positive pathergy test Test interpreted as positive by the physician at 24 to 48 hoursTherapeutics and Clinical Risk Management 2009:5 387
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considerable side effects (neuropathy, constipation) and for 
obvious reasons should be avoided in women with childbear-
ing potential unless they adhere to stringent anticonceptive 
measures. Pentoxifylline, which reduces the production of 
inflammatory cytokines like TNF-α, was effective in reduc-
ing the frequency and severity of oral and vaginal ulcers.15 
Alternative treatment for mucocutaneous involvement are 
dapsone16 and cyclosporine. Cyclosporine is used infrequently 
for this indication for fear of side effects.17 Nevertheless, 
cyclosporine resulted in significantly more alleviation of 
oral aphthous ulcers versus colchicine in a study by Masuda 
and colleagues.18
If there is only mucocutaneous involvement, locally applied 
corticosteroids may suffice. However, involvement of internal 
organs or brain may require much more aggressive treatment 
consisting of systemic corticosteroids of 1 mg/kg/day 
and immunosuppressive drugs. Sulfasalazine is mainly 
effective in arthritis and gastrointestinal involvement.4,19 
Azathioprine and cyclosporine are considered effective 
treatment especially in uveitis. Azathioprine has also been 
used in the treatment of neurologic and gastrointestinal 
involvement. Azathioprine and cyclosporine are often used 
in combination.19 One of the newer immunosuppressive 
drugs, mycophenolic acid derivates, although not effective 
in mucocutaneous lesions,20 can be effective in therapy 
refractory gastrointestinal involvement.21
Vasculitis (large vessel) especially, often involving 
the pulmonary arteries and neurological disease, calls for 
intensive measures as they can be life-threatening. In these 
cases, the use of cyclophosphamide alone or in combination 
with prednisone is warranted.22,23 In life-threatening 
situations, cyclophosphamide should not be used without 
corticosteroids.
Interestingly, although the cause of Behçet’s disease is 
unknown, treatment with high dose penicillin either alone 
or in combination with colchicine was effective in reducing 
symptoms (mucocutaneous and joint manifestations) in 
several studies. A possible role for streptococcal infection 
has been proposed.24–26
In some patients these therapies are either ineffective or 
are associated with intolerable adverse effects necessitating 
alternative treatment strategies. In the slipstream of the 
therapeutical management of rheumatoid arthritis, interest-
ing agents targeting the factors believed to be involved in 
the pathogenesis of Behçet’s disease have been tried in these 
patients with sometimes astonishing results.
emerging treatment options
As mentioned above, T-cells and cytokines are believed to 
play an important role in the pathogenesis of Behçet’s dis-
ease. Emerging therapies aim at influencing T-cell function 
or cytokines.
interferon-alpha
Perhaps interferon-alpha (IFN-α) no longer deserves to be 
called an emerging therapy as it has been used for therapy in 
Table 2 Current treatment used for Behçet’s disease
Medication Dose Main indications
Prednisone Local systemic: 0.5–1 mg/kg Uveitis, Mucocutaneous involvement, induction 
treatment uveitis, Neurological involvement  
Refractory arthritis, Gastrointestinal ulceration
Colchicine 0.5–1.5 mg/day Skin involvement,   Arthritis
Dapsone 100 mg/day Mucocutaneous involvement Arthritis
Azathioprine 2–3 mg/kg/day Uveitis
Pentoxifylline 1200 mg/day Mucocutaneous involvement
Sulfasalazine 1–3 g/day Mucocutaneous involvement, Arthritis
Thalidomide 100–200 mg/day Refractory mucocutaneous involvement
Cyclosporine 3–5 mg/kg/day in divided doses Uveitis, Mucocutaneous involvement
Methotrexate 7.5–15 mg/week Arthritis, uveitis (rarely)
Cyclophosphamide 750 mg/m 2/mo iv Life-threatening involvement (vasculitis, neurological)
iFN-α2a 9 million units three times per week for three months 
followed by a low maintenance dose of 3 million units 
three times per week)
Uveitis
TNF-α blockers various doses Uveitis Arthritis Gastrointestinal ulceration
Abbreviations: iFN, interferon;   TNF, tumor necrosis factor.Therapeutics and Clinical Risk Management 2009:5 388
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refractory Behçet’s disease for over ten years.27 IFN-α has 
been reported to restore the low natural killer cell activity 
in patients with Behçet disease to a near normal level. 
A double-blind study assigned 50 patients to receive either 
IFN-α2Aa (6 million units three times weekly) or placebo 
for three months.28 Significant decreases in pain and duration 
of oral ulcers, frequency of genital lesions, and number of 
pustular papules were noted in patients receiving IFN-α2a. 
The frequency and duration of erythema nodosum-like 
lesions and thrombophlebitis were also decreased in the 
same group. In a systematic review of 32 studies and 
four published abstracts published before 2002, a total of 
338 patients received either IFN-α2a or 2b of various doses.29 
Within a few months of therapy, 86% of the patients with 
mucocutaneous symptoms, 96% with arthritis, and 94% with 
uveitis exhibited a partial or complete response. Significant 
improvements were also found in erythema nodosum-like 
lesions, skin ulcerations, and superficial thrombophlebitis. 
Interferon-α2a seems to be more efficacious than IFN-α2b. 
Compared with low-dose regimens, high-dose regimens were 
more effective and achieved more post-treatment remissions. 
However, disease activity generally returned to baseline 
level either immediately after or up to seven months after 
therapy was discontinued. Side effects of IFN-α include 
mild alopecia, mild leukopenia (generally reversible with 
discontinuing interferon), influenza-like symptoms, and 
depression or psychosis. The recommended regimen is a high 
dose of IFN-α-2a (9 million units three times per week) for 
three months followed by a low maintenance dose (3 million 
units three times per week).
TNF blockers
TNF blockers represent a novel regimen of drugs in the 
treatment of Behçet’s disease in which Th-1 proinflammatory 
cytokines such as IL-1-β, IFN-γ, IL-12, and TNF-α are 
involved in the inflammatory response that is held responsible 
for disease-related symptoms. It is believed that TNF-α 
plays a central role in the inflammatory process of Behçet’s 
disease. Infliximab is a chimeric TNF-α antibody that 
has been reported effective in more than 10 small studies 
of a total of more than 120 patients and 115 other single 
Behçet’s disease cases of refractory mucocutaneous lesions, 
severe gastrointestinal or neurological involvement, and 
ocular disease. One of the most significant studies was pub-
lished in 2004 by Sfikakis and colleagues.30 In this study, 
25 patients with ocular disease were treated with a single 
infusion of 5 mg/kg infliximab. In all but one patient ocular 
inflammation was controlled within one day. In general, 
remarkable and swift improvement or complete resolution 
of the orogenital ulcers, gastrointestinal ulcerations, and 
other Behçet’s disease-related symptoms can be achieved 
shortly after one or two infusions of infliximab at various 
doses ranging from 3–10 mg/kg. A dose of 300–500 mg 
is generally accepted effective, but the time of interval 
and duration of therapy remain undetermined. In patients 
with acute, unilateral, posterior uveitis and significant 
reduction of visual acuity (0.2), as well as in those cases 
with inflammation of the macular area, a single infusion of 
infliximab, or intravitreal steroids may be superior to other 
immunosuppressive drugs. In cases of bilateral posterior eye 
segment inflammation, a single infusion of infliximab could 
be used as a first-line agent to achieve a fast-onset response, 
along with the initiation of other immunosuppressive drugs. 
However, if the ocular disease remains uncontrolled, a 
combination of immunosuppressive regimens with repetitive 
infusions of infliximab 5 mg/kg every 6–8 weeks for up to 
two years can be used.
Another TNF-α blocker used in Behçet’s disease 
is the fusion protein, etanercept. One double-blind, 
placebo-controlled study has been conducted by Melikoglu 
and colleagues.31 This study involved 40 male patients with 
mainly mucocutaneous disease randomly treated with either 
four weeks of 25 mg etanercept (subcutaneously twice a 
week) or placebo. Significant improvements of oral ulcers 
and nodular and papulopustular lesions were observed in the 
etanercept group. Within four weeks, 45% of the etanercept 
group remained free of oral ulcers compared with only 5% 
in the placebo group. No significant improvement in genital 
ulcers or pathergy positivity was observed. Eighty-five per-
cent of the patients receiving etanercept were free of nodular 
lesions compared with 25% of those in the placebo group. 
Most patients experienced recurrent disease three months 
after etanercept was stopped. Other case reports included 
less than 10 Behçet’s disease patients successfully treated 
with etanercept.
Even fewer studies were performed with adalimumab, a 
human TNF-α antibody. In 2006, two groups reported nine 
refractory Behçet’s disease patients. In both retrospective 
studies, various symptoms in all patients resolved swiftly 
and persistently.32,33 Adalumimab could be given for at least 
three years without serious adverse effects. The role of TNF 
blockers in patients with uveitis is currently accepted for 
selected cases. Although reportedly very effective in Behçet’s 
disease, the place of TNF-α blockers in the therapeutic strat-
egy, its long-term effects, and the timing of intervals still 
need to be investigated in more robust and fully powered Therapeutics and Clinical Risk Management 2009:5 389
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randomized trials. TNF blockers should be started as add-on 
strategy in combination with other drugs.
Anti-iL-1 and anti-iL-6
Apart from TNF-α, other cytokines such as IL-1 and 
IL-6 may play a role in the disease. Some studies report 
significantly higher IL-1 levels in patients with both active 
and inactive Behçet’s disease compared to controls, although 
this is not a universal finding. A recent case report describes a 
patient with refractory Behçet’s disease responding rapidly to 
treatment with daily anti-IL-1. Lowering the dose to alternate 
day injections led to an increase in disease activity, again 
responding to an increase in the dose.34
IL-6 levels have been reported to be elevated in the 
cerebrospinal fluid of patients with active neuro-Behçet’s 
disease. IL-6 has a major role in growth and differentiation 
of T cells, antibody production by B cells, and differentia-
tion of macrophages. Inhibition of IL-6 signaling could be 
a new therapeutic regimen for neuro-Behçet’s disease.35 
Tocilizumab is a humanized monoclonal antibody that binds 
both to soluble and to membrane-bound IL-6 receptor and 
has been shown to be effective in rheumatoid arthritis. This 
drug may potentially have an effect in Behçet’s disease. 
However, data on treatment are lacking so far.
Conclusions
Nowadays, many treatment options have become available for 
Behçet’s disease. Few have been examined in double-blind 
trials and most treatments aim to relieve symptoms rather than 
cure the disease. Treatment should be tailored depending on 
the severity of disease. Newer drugs (biologics) influencing 
cytokines and thereby T-cell function are promising without 
very many side effects. Unfortunately, biologics are still 
expensive and long-term effects are still unknown.
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